Equity grants to Vera Therapeutics (VERA) Chief Legal Officer detailed in Form 4

Rhea-AI Filing Summary

Vera Therapeutics Chief Legal Officer Jane Wright-Mitchell received new equity awards. She was granted a stock option for 56,850 shares of Class A Common Stock at an exercise price of $40.73 per share, expiring on March 22, 2036.

She also received 42,403 restricted stock units under the 2024 Inducement Plan, representing 42,403 shares of Class A Common Stock. According to the vesting terms, one-fourth of the RSUs vest on each of May 20, 2027, 2028, 2029 and 2030, while the option vests 12/48ths on March 23, 2027 and 1/48th monthly thereafter, in each case contingent on continued service.

Insights

Equity compensation analyst

Routine, service-based equity grants to Vera’s CLO with multi-year vesting.

The reporting person, Vera Therapeutics’ Chief Legal Officer, received a stock option over 56,850 shares at an exercise price of $40.73 and 42,403 RSUs. Both are compensation-related awards, not open-market purchases or sales, and therefore carry limited signaling value about near-term stock expectations.

The awards vest over several years, with RSUs vesting in four annual tranches starting May 20, 2027, and the option vesting partly on March 23, 2027 then monthly. This structure is typical for retention and alignment with long-term company performance rather than short-term trading intent.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wright-Mitchell Jane

(Last) (First) (Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/23/2026		A		42,403(1)	A	$0	42,403	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$40.73	03/23/2026		A		56,850		(2)	03/22/2036	Class A Common Stock	56,850	$0	56,850	D

Explanation of Responses:

1. Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2024 Inducement Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of May 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date.

2. 12/48ths of the shares subject to the stock option will vest and become exercisable on March 23, 2027, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.

	/s/ Joseph R. Young, Attorney-in-Fact	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Vera Therapeutics (VERA) grant to its Chief Legal Officer?

Vera Therapeutics granted its Chief Legal Officer a stock option over 56,850 shares at an exercise price of $40.73, plus 42,403 restricted stock units. These awards provide potential future ownership in Class A Common Stock, subject to multi-year vesting and continued service conditions.

How do the new RSUs for Vera Therapeutics (VERA) Chief Legal Officer vest?

The 42,403 RSUs vest in four equal annual installments. One-fourth vests on each of May 20, 2027, 2028, 2029 and 2030, rounded to the nearest whole share, provided the Chief Legal Officer remains in continuous service through each vesting date.

What are the vesting terms of the new Vera Therapeutics (VERA) stock option grant?

The stock option over 56,850 shares vests 12/48ths on March 23, 2027, then 1/48th monthly on the same day thereafter. Vesting continues only while the Chief Legal Officer maintains continuous service, and the option expires on March 22, 2036.

Is the Vera Therapeutics (VERA) Form 4 transaction a stock purchase or sale?

The Form 4 reports equity awards, not open-market trades. The Chief Legal Officer acquired 56,850 stock options and 42,403 RSUs as compensation grants, both at a price of $0.00 per share, with vesting conditions rather than immediate cash purchases or sales.

What plan governs the new RSU grant reported by Vera Therapeutics (VERA)?

The 42,403 restricted stock units were granted under Vera Therapeutics’ 2024 Inducement Plan. Each RSU represents one share of Class A Common Stock, and the award is subject to the plan’s terms, including the specified annual vesting schedule and continuous service requirement.